BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 31512980)

  • 21. MARK4 Inhibited by AChE Inhibitors, Donepezil and Rivastigmine Tartrate: Insights into Alzheimer's Disease Therapy.
    Shamsi A; Anwar S; Mohammad T; Alajmi MF; Hussain A; Rehman MT; Hasan GM; Islam A; Hassan MI
    Biomolecules; 2020 May; 10(5):. PubMed ID: 32443670
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tau therapeutic strategies for the treatment of Alzheimer's disease.
    Churcher I
    Curr Top Med Chem; 2006; 6(6):579-95. PubMed ID: 16712493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis, molecular docking and inhibition studies of novel 3-N-aryl substituted-2-heteroarylchromones targeting microtubule affinity regulating kinase 4 inhibitors.
    Parveen I; Khan P; Ali S; Hassan MI; Ahmed N
    Eur J Med Chem; 2018 Nov; 159():166-177. PubMed ID: 30290280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Attenuation of synaptic toxicity and MARK4/PAR1-mediated Tau phosphorylation by methylene blue for Alzheimer's disease treatment.
    Sun W; Lee S; Huang X; Liu S; Inayathullah M; Kim KM; Tang H; Ashford JW; Rajadas J
    Sci Rep; 2016 Oct; 6():34784. PubMed ID: 27708431
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MARK4 and MARK3 associate with early tau phosphorylation in Alzheimer's disease granulovacuolar degeneration bodies.
    Lund H; Gustafsson E; Svensson A; Nilsson M; Berg M; Sunnemark D; von Euler G
    Acta Neuropathol Commun; 2014 Feb; 2():22. PubMed ID: 24533944
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments.
    Schneider A; Biernat J; von Bergen M; Mandelkow E; Mandelkow EM
    Biochemistry; 1999 Mar; 38(12):3549-58. PubMed ID: 10090741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rosmarinic Acid Exhibits Anticancer Effects via MARK4 Inhibition.
    Anwar S; Shamsi A; Shahbaaz M; Queen A; Khan P; Hasan GM; Islam A; Alajmi MF; Hussain A; Ahmad F; Hassan MI
    Sci Rep; 2020 Jun; 10(1):10300. PubMed ID: 32587267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microtubule-affinity regulating kinase family members distinctively affect tau phosphorylation and promote its toxicity in a Drosophila model.
    Sultanakhmetov G; Kato I; Asada A; Saito T; Ando K
    Genes Cells; 2024 Apr; 29(4):337-346. PubMed ID: 38329182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of lisinopril in the therapeutic management of cardiovascular disease by targeting microtubule affinity regulating kinase 4: molecular docking and molecular dynamics simulation approaches.
    Atiya A; Alsayari A; Bin Muhsinah A; Almaghaslah D; Bilgrami AL; Abdulmonem WA; Alorfi NM; DasGupta D; Ashraf GM; Shamsi A; Shahwan M
    J Biomol Struct Dyn; 2023; 41(18):8824-8830. PubMed ID: 36376029
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microtubule-associated protein/microtubule affinity-regulating kinase (p110mark). A novel protein kinase that regulates tau-microtubule interactions and dynamic instability by phosphorylation at the Alzheimer-specific site serine 262.
    Drewes G; Trinczek B; Illenberger S; Biernat J; Schmitt-Ulms G; Meyer HE; Mandelkow EM; Mandelkow E
    J Biol Chem; 1995 Mar; 270(13):7679-88. PubMed ID: 7706316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of human microtubule affinity-regulating kinase 4 inhibitors: fluorescence binding studies, enzyme, and cell assays.
    Naz F; Sami N; Naqvi AT; Islam A; Ahmad F; Imtaiyaz Hassan M
    J Biomol Struct Dyn; 2017 Nov; 35(14):3194-3203. PubMed ID: 27748164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure and dynamics of inactive and active MARK4: conformational switching through the activation process.
    Ahrari S; Mogharrab N; Navapour L
    J Biomol Struct Dyn; 2020 May; 38(8):2468-2481. PubMed ID: 31411112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-based investigation of MARK4 inhibitory potential of Naringenin for therapeutic management of cancer and neurodegenerative diseases.
    Anwar S; Khan S; Shamsi A; Anjum F; Shafie A; Islam A; Ahmad F; Hassan MI
    J Cell Biochem; 2021 Oct; 122(10):1445-1459. PubMed ID: 34121218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of glioblastoma multiforme associated mutations on the structure and function of MAP/microtubule affinity regulating kinase 4.
    Naqvi AAT; Jairajpuri DS; Hussain A; Hasan GM; Alajmi MF; Hassan MI
    J Biomol Struct Dyn; 2021 Mar; 39(5):1781-1794. PubMed ID: 32141394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Virtual screening, pharmacokinetics, molecular dynamics and binding free energy analysis for small natural molecules against cyclin-dependent kinase 5 for Alzheimer's disease.
    Shukla R; Singh TR
    J Biomol Struct Dyn; 2020 Jan; 38(1):248-262. PubMed ID: 30688165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanistic insights into MARK4 inhibition by galantamine toward therapeutic targeting of Alzheimer's disease.
    Adnan M; DasGupta D; Anwar S; Shamsi A; Siddiqui AJ; Snoussi M; Bardakci F; Patel M; Hassan MI
    Front Pharmacol; 2023; 14():1276179. PubMed ID: 37795023
    [No Abstract]   [Full Text] [Related]  

  • 37.
    Ahmed Atto Al-Shuaeeb R; Abd El-Mageed HR; Ahmed S; Mohamed HS; Hamza ZS; Rafi MO; Ahmad I; Patel H
    J Biomol Struct Dyn; 2023; 41(23):14484-14496. PubMed ID: 37184133
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alzheimer-like changes in microtubule-associated protein Tau induced by sulfated glycosaminoglycans. Inhibition of microtubule binding, stimulation of phosphorylation, and filament assembly depend on the degree of sulfation.
    Hasegawa M; Crowther RA; Jakes R; Goedert M
    J Biol Chem; 1997 Dec; 272(52):33118-24. PubMed ID: 9407097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microtubule-affinity regulating kinase 4: A potential drug target for cancer therapy.
    Anwar S; Shahwan M; Hasan GM; Islam A; Hassan MI
    Cell Signal; 2022 Nov; 99():110434. PubMed ID: 35961526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of selective dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors and their effects on tau and microtubule.
    Wu YW; HuangFu WC; Lin TE; Peng CH; Tu HJ; Sung TY; Sung TY; Yen SC; Pan SL; Hsu KC
    Int J Biol Macromol; 2024 Feb; 259(Pt 1):129074. PubMed ID: 38163507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.